| Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer (NCT03699033) | Stephanie Smiddy | 2018-10-01 |
| PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) (NCT03514719) | Radboud University Medical Center | 2018-10-01 |
| Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC (NCT03654027) | First Affiliated Hospital of Guangxi Medical University | 2018-10-01 |
| Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong (NCT03519958) | AstraZeneca | 2018-09-30 |
| CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma (NCT03656705) | Henan Medical University | 2018-09-29 |
| Exemestane in Post-Menopausal Women With NSCLC (NCT02666105) | Masonic Cancer Center, University of Minnesota | 2018-09-27 |
| A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer (NCT04311034) | RemeGen Co., Ltd. | 2018-09-26 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NCT03599518) | Daiichi Sankyo Co., Ltd. | 2018-09-21 |
| CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation (NCT03911193) | Fondazione Ricerca Traslazionale | 2018-09-21 |
| Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (NCT03485378) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-09-20 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (NCT03412877) | National Cancer Institute (NCI) | 2018-09-06 |
| Cardiopulmonary Toxicity of Thoracic Radiotherapy (NCT03978377) | University Medical Center Groningen | 2018-09-01 |
| Expressiona and Diagnostic Potential of miRNAs in NSCLC (NCT05815407) | Al-Azhar University | 2018-09-01 |
| An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (NCT07271446) | Precision Biotech Taiwan Corp. | 2018-09-01 |
| Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients (NCT05023746) | Genetron Health | 2018-08-30 |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (NCT03633110) | Genocea Biosciences, Inc. | 2018-08-29 |
| Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia (NCT04748523) | Instituto Nacional de Cancerologia de Mexico | 2018-08-29 |
| Phase Ib of L-NMMA and Pembrolizumab (NCT03236935) | The Methodist Hospital Research Institute | 2018-08-27 |
| Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers (NCT03658460) | Aalborg University Hospital | 2018-08-22 |
| A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL) (NCT03645330) | Chugai Pharmaceutical | 2018-08-15 |
| A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT03563716) | Genentech, Inc. | 2018-08-10 |
| QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. (NCT03552718) | NantBioScience, Inc. | 2018-08-10 |
| Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer (NCT03659578) | Sun Yat-sen University | 2018-08-09 |
| Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer (NCT03661567) | Sun Yat-sen University | 2018-08-09 |
| Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients (NCT05129462) | Hunan Province Tumor Hospital | 2018-08-05 |
| Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer (NCT03396497) | Lycera Corp. | 2018-08-03 |
| POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors (NCT04193956) | University Medical Center Groningen | 2018-08-01 |
| Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer (NCT03646994) | Hunan Province Tumor Hospital | 2018-08-01 |
| Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC (NCT03616691) | Samsung Medical Center | 2018-08-01 |
| Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03240393) | Novartis Pharmaceuticals | 2018-07-31 |
| A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer (NCT03594747) | BeiGene | 2018-07-30 |
| A Study of Personalized Neoantigen Cancer Vaccines (NCT03794128) | Gritstone bio, Inc. | 2018-07-25 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| Study to Evaluate CCS1477 in Advanced Tumours (NCT03568656) | CellCentric Ltd. | 2018-07-23 |
| A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (NCT04058704) | Betta Pharmaceuticals Co., Ltd. | 2018-07-20 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (NCT03583086) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC (NCT03557411) | Shandong Cancer Hospital and Institute | 2018-07-09 |
| Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients (NCT03682224) | Southern Illinois University | 2018-07-05 |
| Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients (NCT03613467) | Tang-Du Hospital | 2018-07-04 |
| [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) (NCT03724253) | Advanced Accelerator Applications | 2018-07-03 |
| REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (NCT03515629) | Regeneron Pharmaceuticals | 2018-07-02 |
| 20K Distributed Learning Challenge (NCT03564457) | Maastricht Radiation Oncology | 2018-07-01 |
| High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer (NCT03598517) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2018-07-01 |
| A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes (NCT03710629) | The First Affiliated Hospital of Guangzhou Medical University | 2018-07-01 |
| A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations (NCT03434418) | Duke University | 2018-06-30 |
| Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) (NCT03515837) | Merck Sharp & Dohme LLC | 2018-06-29 |
| Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (NCT03412058) | UNICANCER | 2018-06-27 |
| CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) (NCT03504488) | BioAtla, Inc. | 2018-06-27 |
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer (NCT03425006) | University of Pennsylvania | 2018-06-18 |
| PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL (NCT03543813) | CytomX Therapeutics | 2018-06-15 |
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (NCT03502330) | Yale University | 2018-06-09 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228) | VM Oncology, LLC | 2018-06-08 |
| Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients (NCT03509584) | Assistance Publique Hopitaux De Marseille | 2018-06-07 |
| Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (NCT03553550) | Addario Lung Cancer Medical Institute | 2018-06-01 |
| Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer (NCT03647592) | Hunan Province Tumor Hospital | 2018-06-01 |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer (NCT03574649) | ImmunityBio, Inc. | 2018-06-01 |
| An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT03417037) | Bristol-Myers Squibb | 2018-05-24 |
| Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) (NCT03680183) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2018-05-22 |
| Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors (NCT03490669) | AstraZeneca | 2018-05-21 |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (NCT03505710) | Daiichi Sankyo | 2018-05-21 |
| A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer (NCT03616522) | Abramson Cancer Center at Penn Medicine | 2018-05-21 |
| Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (NCT03520686) | ImmunityBio, Inc. | 2018-05-18 |
| Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (NCT03527251) | Sun Yat-sen University | 2018-05-15 |
| Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate (NCT03311620) | Fox Chase Cancer Center | 2018-05-15 |
| Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS (NCT03496766) | Spanish Lung Cancer Group | 2018-05-07 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (NCT03475953) | Institut Bergonié | 2018-05-04 |
| A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) (NCT03472560) | Pfizer | 2018-05-02 |
| Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer (NCT03461185) | Xinqiao Hospital of Chongqing | 2018-05-01 |
| GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors (NCT03576131) | Genmab | 2018-04-30 |
| Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC (NCT03603262) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-04-25 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) (NCT03425643) | Merck Sharp & Dohme LLC | 2018-04-24 |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors (NCT03518554) | Jacobio Pharmaceuticals Co., Ltd. | 2018-04-23 |
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas (NCT03233724) | National Cancer Institute (NCI) | 2018-04-11 |
| Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC (NCT03425331) | Dana-Farber Cancer Institute | 2018-04-10 |
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) (NCT03473925) | Merck Sharp & Dohme LLC | 2018-04-10 |
| A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence (NCT03560791) | St Elizabeth Healthcare | 2018-04-06 |
| Texture Features and PDL1 in CT-PET 18 FDG (NCT04309422) | University Hospital, Montpellier | 2018-04-01 |
| LIFE - Lung Cancer, Immunotherapy, Frailty, Effect (NCT03870464) | University of Southern Denmark | 2018-04-01 |
| Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer (NCT03519971) | AstraZeneca | 2018-03-29 |
| Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI (NCT04510415) | Hanmi Pharmaceutical Company Limited | 2018-03-29 |
| G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer (NCT03455829) | G1 Therapeutics, Inc. | 2018-03-29 |
| A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals (NCT03710616) | The First Affiliated Hospital of Guangzhou Medical University | 2018-03-24 |
| Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (NCT03382912) | Eli Lilly and Company | 2018-03-22 |
| Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) (NCT03095612) | University of Texas Southwestern Medical Center | 2018-03-22 |
| Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (NCT03382899) | Eli Lilly and Company | 2018-03-19 |
| Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (NCT03447769) | Novartis Pharmaceuticals | 2018-03-16 |
| Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer (NCT03438318) | Regeneron Pharmaceuticals | 2018-03-15 |
| A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers. (NCT03510611) | Betta Pharmaceuticals Co., Ltd. | 2018-03-12 |
| Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NCT03371992) | Nilogen Oncosystems | 2018-03-09 |
| A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (NCT03048136) | Bristol-Myers Squibb | 2018-03-09 |
| CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (NCT03511391) | University Hospital, Ghent | 2018-03-09 |
| Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia (NCT03432637) | Guangzhou Institute of Respiratory Disease | 2018-03-05 |
| Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NCT03228186) | University of Michigan Rogel Cancer Center | 2018-03-05 |
| Effects of Nonintubated Thoracoscopic Lobectomy on Lung Protection (NCT03471884) | National Taiwan University Hospital | 2018-03-01 |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer (NCT03419559) | Iovance Biotherapeutics, Inc. | 2018-02-28 |
| WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC (NCT03481101) | Rigshospitalet, Denmark | 2018-02-28 |
| Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer (NCT03460275) | Sun Yat-sen University | 2018-02-26 |
| Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases (NCT03389399) | University of Colorado, Denver | 2018-02-22 |